IGFBP-3 in Ovarian Cancer Invasion

National Taiwan University logo

National Taiwan University

Status

Unknown

Conditions

Ovarian Carcinoma

Treatments

Procedure: immunohistochemical staining, transfection, invasion assay

Study type

Interventional

Funder types

Other

Identifiers

NCT00154986
NSC93-2314-B-002-168
9361700500

Details and patient eligibility

About

An ovarian cancer cell line (OVTW-59) derived from an ovarian endometrioid carcinoma was established and its sublines, labeled as P0, P1, P2, P3, and P4 with increasing invasion abilities were selected from transwell invasion chambers.Using cDNA microarray and verified with quantitative reverse-transcriptase polymerase chain reaction, we have identified IGFBP-3 as an invasion-suppressor gene. We plan to study the role of IGFBP-3 in ovarian cancer invasion.

Full description

We have successfully established an ovarian cancer cell line (OVTW-59), which was derived from an ovarian endometrioid carcinoma. Its sublines, labeled as P0, P1, P2, P3, and P4 with increasing invasion abilities, were selected from transwell invasion chambers, where P0 represented the original cell line at 100th passage. By using cDNA microarray and verified with quantitative reverse-transcriptase polymerase chain reaction, we have identified the differentially gene expression profiles of these OVTW-59 series cell lines in order to identify the invasion related suppressor and oncogenes from ovarian carcinoma. From these genes, we selected insulin-like growth factor binding protein (IGFBP)-3, which is a suppressor gene, and found it lower expressed in higher-grade tumors and correlated with poor patient survival. In vitro, we found IGFBP-3 related to the inhibition of cancer cell migration. In this study, we plan to setup stable transfected IGFBP-3 cell lines in P0 and P4, and study the relationship among IGFBP-3, metalloproteinase-2 (our previous studies which verified its relationship with tumor invasiveness) and insulin-like growth factor (IGF)-1. We would study the changes in cytoskeletal structures and the known functions of anti-proliferation and apoptosis in IGFBP-3. Furthermore, we would like to investigate the mechanism of IGFBP-3 in the inhibition of invasion/migration of ovarian carcinoma, either signaling through MAPK or PI3K/AKT pathways. Finally, through xenograft, we plan to study for the possible application of IGFBP-3 in ovarian cancer therapy.

Sex

Female

Ages

21 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Ovarian Endometrioid Adenocarcinoma

Exclusion criteria

Other types of ovaria epithelial cell carcinoma

Trial design

Primary purpose

Diagnostic

Allocation

Non-Randomized

Interventional model

Single Group Assignment

Masking

Single Blind

Trial contacts and locations

1

Loading...

Central trial contact

Torng Pao-Ling, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems